Senomyx: financial analysis
Ratios worked out from 9 fiscal years of Senomyx's statements, compared with 87 companies in Diagnostics and Research.
The newest statement on file is for fiscal 2017. The figures below describe that year, not Senomyx today.
Senomyx scorecard#
Passes 3 of the 9 checks that could be worked out. Fiscal year 2017.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 5
- ✓Revenue grew in the newest year27.3%Revenue up 27.3% in fiscal 2017.
- ✗Revenue up more than 5% a year over three years2.0%2.0% a year over the three years to fiscal 2017.
- ✗Faster growth over three years than its peers' median2.0%2.0% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.03 vs -0.24Diluted EPS -0.03 in fiscal 2017 against -0.24 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2017.
Profitability1 of 2
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-4.5%-4.5% against Diagnostics and Research's median of -2.4% (66 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-4.5%-4.5% in fiscal 2017 against -44.1% in 2014.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.6×Current ratio 4.58 at the end of fiscal 2017.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2017.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Profitability#
| Fiscal year | Trend | 2017 | 2016 | 2015 | 2014 | 2013 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -4.5% | -46.7% | -51.0% | -44.1% | -40.7% | -2.4% | 49% |
Growth#
| Fiscal year | Trend | 2017 | 2016 | 2015 | 2014 | 2013 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 27.3% | -7.4% | -10.1% | -5.6% | -6.5% | 6.6% | 85% | |
| Revenue growth, 3 years a year | 2.0% | -7.7% | -7.4% | -4.3% | 0.5% | 3.6% | 43% | |
| Revenue growth, 5 years a year | -1.3% | -6.1% | -2.9% | 12.3% | — | 9.7% | 13% |
Financial strength#
| Fiscal year | Trend | 2017 | 2016 | 2015 | 2014 | 2013 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.58× | 3.68× | 3.05× | 2.60× | 1.89× | 1.97× | 79% | |
| Equity share of assets | 68.0% | 62.3% | 59.9% | 61.7% | 47.3% | 51.8% | 71% |
Cash#
| Fiscal year | Trend | 2017 | 2016 | 2015 | 2014 | 2013 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1 M | $-12 M | $-9 M | $-14 M | $-10 M | $-2 M | 56% | |
| Free cash flow margin | 5.1% | -50.7% | -35.9% | -50.5% | -35.3% | 4.7% | 52% | |
| Capital spending share of revenue | 1.9% | 0.6% | 2.8% | 1.2% | 2.1% | 3.3% | — |
Efficiency#
| Fiscal year | Trend | 2017 | 2016 | 2015 | 2014 | 2013 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 1.14× | 0.82× | 0.70× | 0.69× | 0.62× | 0.63× | 86% |
How each figure is worked out#
- Operating margin
- Operating income as a share of revenue.
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).
Source: Senomyx's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 87 companies in Diagnostics and Research that Senomyx is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Senomyx